查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2002644

表觀遺傳學市場：按產品類型、技術、應用和最終用戶分類－2026-2032年全球市場預測

Epigenetics Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，表觀遺傳學市場價值將達到 19.4 億美元，到 2026 年將成長到 22.5 億美元，到 2032 年將達到 59.6 億美元，複合年成長率為 17.33%。

主要市場統計數據
基準年 2025 19.4億美元
預計年份：2026年 22.5億美元
預測年份 2032 59.6億美元
複合年成長率 (%) 17.33%

表觀遺傳學研究的戰略意義以及推動生命科學領域新的轉化和商業性機會的技術進步框架。

表觀遺傳學正在重塑生命科學界對基因表現調控、疾病發病機制以及在各種應用領域中治療潛力的理解。檢測靈敏度、單細胞層次分析和計算分析的最新進展，使得表觀遺傳學測量對轉化研究人員和商業開發人員更實用。本導言概述了構成此概要的基礎，包括其根本促進因素、技術轉折點和相關人員的需求。

本研究評估了技術融合、多體學整合和不斷發展的經營模式，這些因素共同重新定義了表觀遺傳學研究的轉化軌跡。

表觀遺傳學正步入變革階段，不再侷限於漸進式改進，而是在研究流程、臨床轉化策略和商業性價值鏈中展現出結構性變革。技術整合是這一趨勢的核心。高通量定序、先進質譜和多重檢測技術如今正與機器學習主導的分析方法相結合，從複雜的表觀基因資料集中提取具有臨床意義的訊號。這種融合拓展了研究人員可以提出的問題類型，從繪製細胞狀態圖譜到分析功能失調。

本分析檢視了不斷變化的關稅制度對供應鏈韌性、供應商選擇和融資籌資策略的營運和採購影響。

政策和貿易措施會對支撐表觀遺傳學研究和商業化的供應鏈、設備取得和成本結構產生重大影響。近期關稅調整對進口實驗室設備、專用試劑以及使用特定軟體的服務造成了不利影響。關稅制度和分類的變化會影響研究機構和產業團隊的採購時間、資本規劃和供應商選擇。當單一供應商在關鍵類別中佔據主導地位時，這種影響最為嚴重。

我們建構了一個多層次的細分框架，將產品類型、核心技術、特定領域的應用和不同的最終用戶連結起來，從而支援有針對性的策略決策。

明確分類市場區隔是把表觀遺傳學創新轉化為可行的產品和服務策略的關鍵要素。按產品類型分類，市場可細分為耗材和試劑、儀器以及軟體和服務。耗材和試劑可細分為酵素和修飾試劑以及試劑盒和檢測方法；儀器可細分為質譜儀、微陣列掃描儀、PCR儀和定序系統；軟體和服務則分為合約服務和軟體工具。這種產品類型分類突顯了經常性收入來源與高價值資本投資之間的交集，而這些都需要長期的檢驗和服務生態系統。

比較全球主要地區的採用趨勢、法規預期和能力建設，以完善商業化和夥伴關係策略。

區域趨勢在塑造表觀遺傳學相關工具和應用的全球發展、傳播和商業化過程中發揮著至關重要的作用。美洲地區擁有許多創新中心、活躍的私人資本活動以及緊密交織的製藥和生物技術公司網路，正在加速轉化研究計劃的進展。該地區的研究機構和產業合作夥伴往往主導早期檢驗研究，並塑造先進設備和合約服務的初始市場。

我們評估平台整合、監管合規和附加價值服務模式所帶來的競爭差異化，這些差異化有助於建立永續的客戶關係。

表觀遺傳學領域的競爭動態取決於深厚的科學專業知識、平台穩定性以及提供端到端解決方案的能力，從而降低應用門檻。領先的儀器供應商透過精準的工程設計、可擴展的擴充性以及縮短實用化時間的整合服務模式來脫穎而出。銷售與儀器捆綁銷售的檢驗試劑和檢測試劑盒的公司通常擁有更長的客戶生命週期，從而簡化終端用戶的工作流程並縮短檢驗週期。

領導者面臨的實際策略挑戰是加快部署速度、減少營運摩擦，並使產品和夥伴關係關係策略與臨床和商業性要求保持一致。

產業領導者應優先採取一系列切實可行的步驟，以加速表觀遺傳學的實用化，並在不斷發展的領域中保持競爭優勢。首先，應投資於模組化產品架構和檢驗的試劑組，在減少研究和臨床團隊整合摩擦的同時，實現持續的收入成長。這種方法可以縮短引進週期，並支援在不同的實驗室環境中實現可重複性。

為了支持實際結論，本文檔描述了一種混合研究途徑，該方法結合了與主要相關人員的訪談、技術檢驗審查和嚴格的證據整合。

支持這些研究結果的調查方法結合了對一級資訊來源的訪談、技術檢驗審查，以及對同儕審查文獻和公開監管文件的系統整合。關鍵工作包括與儀器製造商、試劑供應商、學術研究人員、臨床實驗室管理人員和合約研究機構進行對話，以明確實際操作、應用障礙和技術成熟路徑。

策略結論總結，將技術進步、營運準備和夥伴關係模式連結起來，以展示將表觀遺傳學科學轉化為可操作解決方案的可行路徑。

總之，表觀遺傳學是一個快速發展的領域，技術創新、轉換應用和商業性機會在此交會融合。檢測技術、分析方法和表觀基因編輯技術的進步，拓展了研究人員能夠解答的問題範圍和細節程度，從而為診斷和治療方法的開發開闢了新的途徑。營運和政策因素，包括貿易趨勢和供應鏈結構，對企業如何規劃採購和擴展自身能力有顯著的影響。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：表觀遺傳學市場：依產品類型分類

  • 耗材和試劑
    • 酵素和修飾試劑
    • 試劑盒檢測
  • 裝置
    • 質譜儀
    • 微陣列掃描儀
    • PCR裝置
    • 定序系統
  • 軟體服務
    • 合約服務
    • 軟體工具

第9章：表觀遺傳學市場：依技術分類

  • 染色質可及性分析
  • DNA甲基化
  • 表觀基因編輯
  • 組蛋白修飾
  • 非編碼RNA（ncRNA）

第10章：表觀遺傳學市場：依應用領域分類

  • 農業生物技術
  • 自體免疫疾病
  • 心血管疾病
  • 藥物發現
    • 先導化合物的鑑定
    • 毒性測試
  • 感染疾病
  • 代謝性疾病
  • 神經系統疾病
  • 腫瘤學調查
    • 生物標記發現
    • 診斷
    • 治療調查

第11章：表觀遺傳學市場：依最終用戶分類

  • 學術和研究機構
  • 合約研究機構
  • 診斷檢測實驗室
  • 製藥和生物技術公司

第12章：表觀遺傳學市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：表觀遺傳學市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：表觀遺傳學市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國表觀遺傳學市場

第16章：中國表觀遺傳學市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 10X Genomics, Inc.
  • Abcam PLC
  • Active Motif, Inc.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • CellCentric Ltd.
  • Danaher Corporation
  • Diagenode sa
  • Domainex Ltd.
  • Element Biosciences, Inc.
  • EpiGentek Group Inc.
  • Exact Sciences
  • F. Hoffmann-La Roche AG
  • GeneTex, Inc.
  • Illumina, Inc.
  • Ipsen Biopharmaceuticals, Inc.
  • Merck KGaA
  • MorphoSys
  • New England Biolabs, Inc.
  • Pacific Biosciences
  • PerkinElmer, Inc.
  • Promega Corporation
  • QIAGEN NV
  • Thermo Fisher Scientific Inc.
  • Zymo Research Corp.
Product Code: MRR-0D217D5ADE3D

The Epigenetics Market was valued at USD 1.94 billion in 2025 and is projected to grow to USD 2.25 billion in 2026, with a CAGR of 17.33%, reaching USD 5.96 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.94 billion
Estimated Year [2026] USD 2.25 billion
Forecast Year [2032] USD 5.96 billion
CAGR (%) 17.33%

Framing the strategic relevance of epigenetics research and technological advances that are driving new translational and commercial opportunities in life sciences

Epigenetics is reshaping how the life sciences community understands gene regulation, disease etiology, and therapeutic opportunity across a diverse range of applications. Recent advances in assay sensitivity, single-cell resolution, and computational analytics have converged to make epigenetic measurements more actionable for translational researchers and commercial developers alike. This introduction summarizes the underlying drivers, technological inflection points, and stakeholder needs that frame the rest of this executive-level synthesis.

Emerging scientific consensus emphasizes that epigenetic modifications are both markers of cellular state and modulators of function, which creates dual-value propositions for diagnostics and therapeutics. Concurrently, instrument innovation and better reagent chemistry are reducing barriers to routine implementation in both research and clinical contexts. As a result, cross-disciplinary teams from academic labs, contract organizations, diagnostic services, and industry research groups are integrating epigenetic endpoints into study designs to augment molecular readouts with regulatory-layer insights.

Taken together, these forces reiterate an important strategic reality: decision-makers must evaluate not only scientific validity but operational feasibility and partnership models that accelerate translation. This introduction therefore sets expectations for the subsequent sections, which cover landscape shifts, policy impacts, segmentation intelligence, regional dynamics, competitive positioning, actionable recommendations, and the research methodology that supports the conclusions offered here.

Assessing technological convergence, multi-omic integration, and commercial model evolution that are collectively redefining translational trajectories in epigenetics research

Epigenetics has entered a phase characterized by transformative shifts that transcend incremental improvements and point to structural change in research workflows, clinical translational strategies, and commercial value chains. Technological integration is a central theme: high-throughput sequencing, advanced mass spectrometry, and multiplexed assays are now interfacing with machine learning-driven analytics to extract clinically relevant signals from complex epigenomic datasets. This convergence is expanding the types of questions researchers can ask, from cell-state mapping to functional perturbation analysis.

Another major shift is the normalization of multi-omic study designs that position epigenetic data alongside genomic, transcriptomic, proteomic, and metabolomic layers. This systemic view improves biomarker robustness and supports mechanistic insights for therapeutic intervention. In parallel, the maturation of epigenome editing tools is opening therapeutic pathways that were previously conceptual, enabling targeted modulation of gene regulation with increasing specificity and improved delivery strategies.

Finally, commercial and operational shifts are apparent. Contract research providers and diagnostic laboratories are embedding epigenetic assays into service portfolios, and cross-sector partnerships are accelerating commercialization timelines for both tools and therapeutics. These shifts require adaptive business models that combine scientific excellence with scalable manufacturing, regulatory strategy, and validation pathways designed to meet clinical-grade evidence standards. Collectively, these transformational forces are redefining the boundaries of what is scientifically feasible and commercially viable within epigenetics.

Analyzing the operational and procurement implications of evolving tariff regimes that are reshaping supply chain resilience, vendor selection, and capital acquisition strategies

Policy and trade measures can materially influence supply chains, instrument access, and cost structures that underlie epigenetics research and commercialization. Recent tariff adjustments have introduced headwinds that affect imported laboratory instruments, specialized reagents, and certain software-enabled services. Changes to duty regimes and customs classifications influence procurement timing, capital planning, and vendor selection for research institutions and industry teams, and they are most acute where single-source suppliers dominate critical categories.

Operational teams have responded by diversifying suppliers, pre-negotiating long-lead procurement contracts, and pursuing local sourcing where feasible for reagents and consumables. In parallel, instrument vendors are increasingly offering financing, on-site installation, and bundled service contracts to mitigate acquisition friction introduced by trade measures. These shifts alter total acquisition cost profiles and may favor vendors with localized manufacturing or established distribution networks.

Importantly, businesses that invest in supply chain resilience and flexible procurement strategies gain competitive advantage. Risk mitigation practices, such as maintaining multi-vendor specifications, second-source reagent validation, and regional logistics planning, improve continuity of research operations. From a strategic perspective, understanding the cumulative operational implications of tariff changes enables stakeholders to prioritize investments that sustain productivity while preserving options for future scaling and regulatory compliance.

Developing a layered segmentation framework that links product categories, core technologies, domain-specific applications, and varied end users to inform targeted strategic decisions

Segmentation clarity is a foundational element for translating epigenetics innovation into actionable product and service strategies. Across product types, the landscape is categorized into consumables and reagents, instruments, and software and services, with consumables and reagents further differentiating into enzymes and modification reagents and kits and assays, instruments subdivided into mass spectrometers, microarray scanners, PCR instruments, and sequencing systems, and software and services separating into contract services and software tools. This product-type breakdown highlights where recurring revenue streams intersect with high-capital purchases that require extended validation and service ecosystems.

From a technology perspective, the field encompasses chromatin accessibility assays, DNA methylation, epigenome editing, histone modification, and non-coding RNA modalities, each with distinct experimental requirements, analytical pipelines, and translational use cases. These technology distinctions inform R&D prioritization because assay complexity, throughput, and interpretive frameworks differ significantly across the set.

Application segmentation reflects a broad set of research and development imperatives including agricultural biotechnology, autoimmune diseases, cardiovascular diseases, drug discovery, infectious diseases, metabolic disorders, neurological disorders, and oncology research, where drug discovery itself bifurcates into lead identification and toxicology studies and oncology research further divides into biomarker discovery, diagnostics, and therapeutic research. This application orientation clarifies end-user needs and evidentiary thresholds for analytic validity, clinical utility, and regulatory acceptance.

End-user segmentation includes academic and research institutes, contract research organizations, diagnostic laboratories, and pharmaceutical and biotechnology companies, and it underscores variation in budget cycles, procurement drivers, and adoption velocity. Taken together, this layered segmentation framework enables more precise competitive targeting, product roadmapping, and partnership strategies by aligning technical capabilities with end-user workflows and unmet needs.

Comparing regional adoption dynamics, regulatory expectations, and capacity building across major world regions to refine commercialization and partnership strategies

Regional dynamics play a decisive role in shaping how epigenetics tools and applications evolve, diffuse, and commercialize globally. The Americas exhibit concentrated centers of innovation, strong private capital activity, and dense networks of pharmaceutical and biotech companies that accelerate translational projects. Research institutions and industry partners in the region often drive early validation studies and form the initial markets for advanced instruments and contract services.

Europe, Middle East & Africa combine regulatory complexity with heterogeneous research infrastructure; while some countries host world-class translational capabilities, others are in earlier stages of adoption. This region places particular emphasis on harmonized clinical evidence and regulatory alignment, which influences study design and data interoperability. Partnerships that bridge national research centers and public health systems can facilitate broader access to epigenetic diagnostics and therapeutic trials.

Asia-Pacific is characterized by rapid capacity building, increasing investment in domestic instrument and reagent production, and growing emphasis on local clinical validation. Academic and industrial investments in the region are expanding both basic science pipelines and applied therapeutic research. Supply chain considerations and local manufacturing capacity also inform vendor strategies, with an emphasis on scalable distribution and service networks that support regional adoption.

Understanding these regional nuances allows stakeholders to align commercialization tactics, clinical collaboration models, and supply chain strategies with the distinctive regulatory environments, funding structures, and adoption pathways that shape demand across the Americas, Europe, Middle East & Africa, and Asia-Pacific.

Evaluating competitive differentiation driven by platform integration, regulatory readiness, and value-added service models that underpin durable customer relationships

Competitive dynamics in epigenetics are defined by a combination of deep scientific expertise, platform robustness, and the ability to deliver end-to-end solutions that lower barriers to adoption. Leading instrument vendors differentiate through precision engineering, throughput scalability, and integrated service models that reduce the time from purchase to productive use. Companies that bundle validated reagents and assay kits with instruments often secure longer customer lifecycles because they simplify operational workflows and shorten validation timelines for end users.

Software and analytics providers compete on algorithmic transparency, ease of integration with laboratory information management systems, and the capacity to handle multi-omic datasets at scale. Contract services players that can rapidly operationalize complex epigenetic assays for translational studies, clinical validation, and toxicology testing are in a position to capture demand from sponsors seeking to outsource specialized workflows.

Strategic alliances and licensing arrangements are common, as firms leverage complementary capabilities to accelerate product development and market entry. Firms that invest in regulatory evidence packages, robust clinical validation, and repeatable quality systems gain credibility with institutional customers and clinical partners. Ultimately, competitive advantage accrues to organizations that combine scientific leadership with operational excellence, flexible commercial models, and the capacity to support customers across the research-to-clinic continuum.

Practical strategic imperatives for leaders to accelerate adoption, reduce operational friction, and align product and partnership strategies with clinical and commercial requirements

Industry leaders should prioritize a set of actionable steps that accelerate translation and secure competitive advantage in the evolving epigenetics landscape. First, invest in modular product architectures and validated reagent kits that lower integration friction for research and clinical teams while enabling recurring revenue. This approach shortens onboarding cycles and supports reproducibility across diverse laboratory settings.

Second, build strategic partnerships that combine instrument capabilities with analytics and contract services to deliver turnkey solutions for translational programs. Collaborative models that share development risk and co-develop validation pathways enhance market access and reduce time to clinical utility. Third, strengthen supply chain resilience through diversified sourcing, regional warehousing, and second-source validation for critical reagents to mitigate exposure to trade fluctuations and logistics disruptions.

Fourth, commit to rigorous evidence generation that addresses clinical validity, utility, and analytical performance to meet regulatory and payer expectations. Fifth, tailor go-to-market strategies by region and end user: align pricing, service levels, and training programs with local adoption patterns and regulatory requirements. Finally, invest in talent and cross-disciplinary teams that bridge assay chemistry, instrumentation, and computational biology to sustain innovation and operational delivery over the medium term.

Describing a mixed-methods research approach that integrates primary stakeholder interviews, technology validation reviews, and rigorous evidence synthesis to support practical conclusions

The research methodology underpinning these insights combines primary source interviews, technology validation reviews, and structured synthesis of peer-reviewed literature and public regulatory documentation. Primary engagement included conversations with instrument manufacturers, reagent suppliers, academic investigators, clinical laboratory directors, and contract research providers to surface operational realities, adoption barriers, and technology maturation pathways.

Technology validation reviews evaluated assay performance attributes, workflow complexity, and integration needs across key epigenetics modalities such as chromatin accessibility assays and DNA methylation profiling. Evidence synthesis prioritized peer-reviewed studies, preprints with replication cohorts, and regulatory guidance documents where applicable, while explicitly weighting translational relevance and reproducibility.

Analytical triangulation reconciled qualitative inputs with documented product capabilities and published validation studies to produce balanced judgments about strategic implications without relying on proprietary market estimates. Where trade and policy impacts were examined, the methodology incorporated customs documentation, tariff schedules, and vendor supply chain disclosures to assess operational implications and mitigation strategies. This mixed-methods approach ensures that conclusions are grounded in verifiable technical evidence and stakeholder experience.

Summarizing strategic conclusions that connect technological progress, operational readiness, and partnership models to actionable paths for translating epigenetic science into practical solutions

In closing, epigenetics represents a rapidly maturing domain where technical innovation, translational ambition, and commercial opportunity intersect. Advances in assay technology, analytics, and epigenome editing are expanding both the scope and the granularity of questions that researchers can answer, which in turn creates new pathways for diagnostics and therapeutic development. Operational and policy factors, including trade dynamics and supply chain configuration, materially affect how organizations plan procurement and scale capabilities.

Decision-makers should therefore align scientific strategy with operational readiness, regulatory planning, and partnership models that accelerate product validation and clinical integration. By combining modular product designs, evidence-focused development, supply chain resilience, and tailored regional strategies, organizations can transform epigenetic potential into measurable impact for patients and customers. The conclusions presented here serve as a roadmap for leaders intent on translating complex science into robust, reproducible, and commercially viable solutions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Epigenetics Market, by Product Type

  • 8.1. Consumables & Reagents
    • 8.1.1. Enzymes & Modification Reagents
    • 8.1.2. Kits & Assays
  • 8.2. Instruments
    • 8.2.1. Mass Spectrometers
    • 8.2.2. Microarray Scanners
    • 8.2.3. PCR Instruments
    • 8.2.4. Sequencing Systems
  • 8.3. Software & Services
    • 8.3.1. Contract Services
    • 8.3.2. Software Tools

9. Epigenetics Market, by Technology

  • 9.1. Chromatin Accessibility Assays
  • 9.2. DNA Methylation
  • 9.3. Epigenome Editing
  • 9.4. Histone Modification
  • 9.5. Non-coding RNA (ncRNA)

10. Epigenetics Market, by Application

  • 10.1. Agricultural Biotechnology
  • 10.2. Autoimmune Diseases
  • 10.3. Cardiovascular Diseases
  • 10.4. Drug Discovery
    • 10.4.1. Lead Identification
    • 10.4.2. Toxicology Studies
  • 10.5. Infectious Diseases
  • 10.6. Metabolic Disorders
  • 10.7. Neurological Disorders
  • 10.8. Oncology Research
    • 10.8.1. Biomarker Discovery
    • 10.8.2. Diagnostics
    • 10.8.3. Therapeutic Research

11. Epigenetics Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Diagnostic Laboratories
  • 11.4. Pharmaceutical & Biotechnology Companies

12. Epigenetics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Epigenetics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Epigenetics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Epigenetics Market

16. China Epigenetics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 10X Genomics, Inc.
  • 17.6. Abcam PLC
  • 17.7. Active Motif, Inc.
  • 17.8. Agilent Technologies, Inc.
  • 17.9. Bio-Rad Laboratories, Inc.
  • 17.10. CellCentric Ltd.
  • 17.11. Danaher Corporation
  • 17.12. Diagenode s.a.
  • 17.13. Domainex Ltd.
  • 17.14. Element Biosciences, Inc.
  • 17.15. EpiGentek Group Inc.
  • 17.16. Exact Sciences
  • 17.17. F. Hoffmann-La Roche AG
  • 17.18. GeneTex, Inc.
  • 17.19. Illumina, Inc.
  • 17.20. Ipsen Biopharmaceuticals, Inc.
  • 17.21. Merck KGaA
  • 17.22. MorphoSys
  • 17.23. New England Biolabs, Inc.
  • 17.24. Pacific Biosciences
  • 17.25. PerkinElmer, Inc.
  • 17.26. Promega Corporation
  • 17.27. QIAGEN N.V.
  • 17.28. Thermo Fisher Scientific Inc.
  • 17.29. Zymo Research Corp.

LIST OF FIGURES

  • FIGURE 1. GLOBAL EPIGENETICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL EPIGENETICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL EPIGENETICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL EPIGENETICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL EPIGENETICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL EPIGENETICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL EPIGENETICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL EPIGENETICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES EPIGENETICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA EPIGENETICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL EPIGENETICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL EPIGENETICS MARKET SIZE, BY ENZYMES & MODIFICATION REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL EPIGENETICS MARKET SIZE, BY ENZYMES & MODIFICATION REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL EPIGENETICS MARKET SIZE, BY ENZYMES & MODIFICATION REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL EPIGENETICS MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL EPIGENETICS MARKET SIZE, BY KITS & ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL EPIGENETICS MARKET SIZE, BY KITS & ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL EPIGENETICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL EPIGENETICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL EPIGENETICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL EPIGENETICS MARKET SIZE, BY MASS SPECTROMETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL EPIGENETICS MARKET SIZE, BY MASS SPECTROMETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL EPIGENETICS MARKET SIZE, BY MASS SPECTROMETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL EPIGENETICS MARKET SIZE, BY MICROARRAY SCANNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL EPIGENETICS MARKET SIZE, BY MICROARRAY SCANNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL EPIGENETICS MARKET SIZE, BY MICROARRAY SCANNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL EPIGENETICS MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL EPIGENETICS MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL EPIGENETICS MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL EPIGENETICS MARKET SIZE, BY SEQUENCING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL EPIGENETICS MARKET SIZE, BY SEQUENCING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL EPIGENETICS MARKET SIZE, BY SEQUENCING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL EPIGENETICS MARKET SIZE, BY CONTRACT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL EPIGENETICS MARKET SIZE, BY CONTRACT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL EPIGENETICS MARKET SIZE, BY CONTRACT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL EPIGENETICS MARKET SIZE, BY SOFTWARE TOOLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL EPIGENETICS MARKET SIZE, BY SOFTWARE TOOLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL EPIGENETICS MARKET SIZE, BY SOFTWARE TOOLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL EPIGENETICS MARKET SIZE, BY CHROMATIN ACCESSIBILITY ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL EPIGENETICS MARKET SIZE, BY CHROMATIN ACCESSIBILITY ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL EPIGENETICS MARKET SIZE, BY CHROMATIN ACCESSIBILITY ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL EPIGENETICS MARKET SIZE, BY DNA METHYLATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL EPIGENETICS MARKET SIZE, BY DNA METHYLATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL EPIGENETICS MARKET SIZE, BY DNA METHYLATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL EPIGENETICS MARKET SIZE, BY EPIGENOME EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL EPIGENETICS MARKET SIZE, BY EPIGENOME EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL EPIGENETICS MARKET SIZE, BY EPIGENOME EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL EPIGENETICS MARKET SIZE, BY HISTONE MODIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL EPIGENETICS MARKET SIZE, BY HISTONE MODIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL EPIGENETICS MARKET SIZE, BY HISTONE MODIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL EPIGENETICS MARKET SIZE, BY NON-CODING RNA (NCRNA), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL EPIGENETICS MARKET SIZE, BY NON-CODING RNA (NCRNA), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL EPIGENETICS MARKET SIZE, BY NON-CODING RNA (NCRNA), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL EPIGENETICS MARKET SIZE, BY AGRICULTURAL BIOTECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL EPIGENETICS MARKET SIZE, BY AGRICULTURAL BIOTECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL EPIGENETICS MARKET SIZE, BY AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL EPIGENETICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL EPIGENETICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL EPIGENETICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL EPIGENETICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL EPIGENETICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL EPIGENETICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL EPIGENETICS MARKET SIZE, BY LEAD IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL EPIGENETICS MARKET SIZE, BY LEAD IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL EPIGENETICS MARKET SIZE, BY LEAD IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL EPIGENETICS MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL EPIGENETICS MARKET SIZE, BY TOXICOLOGY STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL EPIGENETICS MARKET SIZE, BY TOXICOLOGY STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL EPIGENETICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL EPIGENETICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL EPIGENETICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL EPIGENETICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL EPIGENETICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL EPIGENETICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL EPIGENETICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL EPIGENETICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL EPIGENETICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL EPIGENETICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL EPIGENETICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL EPIGENETICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL EPIGENETICS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL EPIGENETICS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL EPIGENETICS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL EPIGENETICS MARKET SIZE, BY THERAPEUTIC RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL EPIGENETICS MARKET SIZE, BY THERAPEUTIC RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL EPIGENETICS MARKET SIZE, BY THERAPEUTIC RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL EPIGENETICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL EPIGENETICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL EPIGENETICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL EPIGENETICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL EPIGENETICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL EPIGENETICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL EPIGENETICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL EPIGENETICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL EPIGENETICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL EPIGENETICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL EPIGENETICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL EPIGENETICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL EPIGENETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS EPIGENETICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA EPIGENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA EPIGENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA EPIGENETICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE EPIGENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST EPIGENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA EPIGENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC EPIGENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL EPIGENETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN EPIGENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. GCC EPIGENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. GCC EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. GCC EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 205. GCC EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 206. GCC EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 207. GCC EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. GCC EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. GCC EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 210. GCC EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 211. GCC EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION EPIGENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS EPIGENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. G7 EPIGENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. G7 EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. G7 EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 235. G7 EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 236. G7 EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 237. G7 EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. G7 EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. G7 EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 240. G7 EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 241. G7 EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. NATO EPIGENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. NATO EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. NATO EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 245. NATO EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 246. NATO EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 247. NATO EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. NATO EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. NATO EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 250. NATO EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 251. NATO EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL EPIGENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES EPIGENETICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA EPIGENETICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)